|

Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet

RECRUITINGN/ASponsored by Universidade Federal do Rio de Janeiro
Actively Recruiting
PhaseN/A
SponsorUniversidade Federal do Rio de Janeiro
Started2022-11-15
Est. completion2024-05
Eligibility
Age20 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04965129

Summary

This study is conducted to test the hypothesis that patients with lung cancer undergoing treatment with immunotherapy, chemotherapy and tyrosine Kinase Inhibitors receiving a high protein diet and supplemented with fish oil will improve muscle mass, therapeutic response and modulate the intestinal microbiota within a 4 month period.

Eligibility

Age: 20 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of non-small cell lung cancer, both sexes, ECOG performance status (0-2) eligible for treatment with immunotherapy, chemotherapy and tyrosine Kinase Inhibitors.

Exclusion Criteria:

* supplementation of PUFA n-3 in the last 6 months; weight loss\> 10% in 6 months, chronic liver disease, previous chronic kidney disease, anorexia, decompensated diabetes mellitus and dementia.

Conditions2

CancerLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.